Some 11% of American adults say they currently take a GLP-1 medication such as Wegovy or Zepbound. That’s according to a fresh Gallup survey conducted in late spring 2026. The figure marks a sharp rise from 3% in 2024. Awareness has climbed even faster. Nearly everyone has now heard of these drugs.
The Surge in Use
Numbers tell a story of rapid adoption. Gallup polled 5,065 U.S. adults between May 28 and June 5, 2026. It found 15% have tried a GLP-1 drug at some point. That’s more than double the 6% from two years earlier. (Gizmodo)
KFF offered a similar picture months earlier. Its October 2025 tracking poll put current use at 12%. Lifetime use reached 18%. Women reported higher rates than men. Fifteen percent of women said they were on the drugs compared with 9% of men. Adults aged 50 to 64 showed the heaviest uptake at 22%. (KFF)
And. These medications first arrived as treatments for type 2 diabetes. Doctors soon noticed dramatic weight loss in patients. Novo Nordisk’s semaglutide won approval for obesity as Wegovy in 2021. Eli Lilly followed with tirzepatide as Zepbound in late 2023. Demand exploded. Prescriptions for obesity indications jumped nearly 587% from 2019 to 2024. (Forbes Health)
Obesity rates tell part of the tale. They hit 39.9% in 2022. The latest self-reported figures show a drop to 36.4%. Many analysts credit the drugs. A decade ago the rate stood at 28.4%. The change feels abrupt. But the data line up.
Users split between brand-name products and compounded versions. Gallup found 68% on brands like Wegovy or Zepbound. Nineteen percent relied on compounded alternatives. Twelve percent weren’t sure. Cost drives many switches. Insurance often refuses to cover weight-loss use. Patients then hunt for cheaper options. (Gizmodo)
Side effects vary. Nausea strikes many, especially early on. Some lose their sense of smell or taste. Others report unexpected benefits. Reduced cravings for alcohol. Less interest in cocaine. Even reports of lower violent behavior. The picture isn’t uniform. Older adults over 65 often see weaker results. Discontinuation rates run high. One study tracked in Forbes Health found 56% stop within a year on average. Weight regain pulls many back. Forty-two percent restart within months of quitting.
Doctors prescribe most of these medications. Seventy-six percent of KFF respondents got them from a physician. Seventeen percent turned to online sources. Payment troubles hit 26% of households in the prior year. The rate climbed higher among uninsured, Black, Hispanic and lower-income groups. Half of all adults called the drugs hard to afford. That included 55% of those with insurance.
Market forces have shifted. Novo Nordisk and Eli Lilly posted massive revenue gains. Novo saw sales of its key drugs drive much of its growth since 2022. Global projections now point to a $200 billion incretin market by 2030. J.P. Morgan researchers estimate 30 million Americans could be on GLP-1 therapy by then. Up from roughly 10 million in 2026. (J.P. Morgan)
Oral Options and Policy Changes Alter the Equation
Delivery methods are changing fast. Injections dominated at first. Then came pills. The FDA approved an oral version of Wegovy in December 2025. Early estimates suggested 400,000 Americans were taking it within 10 weeks. Eli Lilly’s orforglipron pill sits close behind with potential approval in 2026. Clinical data show meaningful weight loss. Up to 11% or more in some trials. Other candidates like aleniglipron and higher-dose formulations promise even more. (CNN)
Prices have started to bend. List prices still exceed $1,000 a month without coverage. Yet savings cards can drop costs to $25 for some commercially insured patients. Novo Nordisk pledged to cut Wegovy to $675 by January 2027. Government programs add pressure. The Medicare GLP-1 Bridge initiative launches this month. It aims to give eligible seniors access through 2027 at potentially $50 a month. A TrumpRX discount program targets even lower out-of-pocket figures for some. Medicaid spending on these drugs soared from $1 billion in 2019 to $8.6 billion in 2024. The trend shows no sign of slowing. (Forbes Health)
Broader health effects keep researchers busy. These drugs lower blood pressure. They cut cardiovascular risk. Some studies link them to fewer substance-use problems. Veterans data from 2026 showed lower rates of addiction disorders among users. Yet the medications aren’t approved for addiction treatment. More than 15 trials now explore that angle. Benefits for heart failure, kidney disease and sleep apnea have won fresh approvals or are under review.
But challenges remain. Compounding pharmacies rushed in during shortages. The FDA moved in February 2026 to crack down on mass-produced unapproved versions. Safety and quality worries drove the action. Supply has improved. Still, access gaps persist by income, race and geography. Younger adults show the fastest prescription growth. Their rates rose nearly 588% from 2019 to 2024.
So what happens next? New dual and triple agonists like CagriSema and retatrutide post even larger weight-loss numbers in trials. Some reach 15% to 21% body weight reduction. Oral drugs could remove the needle barrier for many. Insurance policies continue to evolve. Medicare’s temporary bridge and state Medicaid expansions may pull in millions more. Yet high discontinuation rates and questions about long-term muscle loss or nutritional impacts linger.
Eleven percent today. Projections of 25 million to 30 million users by 2030. The numbers keep climbing. Drugmakers race to meet demand while regulators scramble to ensure safety. Doctors weigh benefits against side effects for each patient. Patients balance cost against results. The experiment plays out in real time across kitchens, clinics and boardrooms. Its full shape is only beginning to emerge.
WebProNews is an iEntry Publication